Last reviewed · How we verify
NCT04626622
Kagocel® for the Prevention of ARVI and Influenza in Young People
trial testing Kagocel in Acute Upper Respiratory Tract Infection in 75 participants. Completed in 30 June 2018.
26 April 2018
Quick facts
| Lead sponsor | Nearmedic Plus LLC |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 15 February 2018 |
| Primary completion | 26 April 2018 |
| Estimated completion | 30 June 2018 |
| Sites | 1 location across Russia |
Drugs / interventions tested
Conditions studied
- Acute Upper Respiratory Tract Infection — all drugs for Acute Upper Respiratory Tract Infection →
- Influenza — all drugs for Influenza →
- Respiratory Viral Infection — all drugs for Respiratory Viral Infection →
Sponsor
Nearmedic Plus LLC — full company profile →
Who can join
Adults 18 to 30, any sex, with Acute Upper Respiratory Tract Infection or Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the use of Kagocel for the prevention of acute respiratory viral infections (ARVI) and influenza during the epidemic rise in the incidence of diseases in Russia in 2018 (epidemiology: the number of cases during the period of Kagocel administration and follow-up, bacterial exacerbations, the number of repeated episodes (reinfection), demographics of patients, safety, adherence to treatment) in students at risk due to stress, lack of sleep and fatigue.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04626622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Kagocel
Trials testing the same drug.
- NCT04611061 — Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers · completed
- NCT04651491 — Treatment of Influenza and ARVI in Children by Kagocel ® · completed
Other Nearmedic Plus LLC trials
Trials by the same sponsor.
- NCT04150224 — Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169 · Phase 1 · completed
- NCT04664127 — Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyc · completed
- NCT03677258 — Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy · NA · completed
- NCT04611061 — Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers · completed
- NCT03334734 — Phase 2a Study of PBTZ169 · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04626622 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nearmedic Plus LLC
- Last refreshed: 12 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04626622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing